Skip to main content

Table 1 Eptinezumab Clinical Studies

From: Cardiovascular outcomes in adults with migraine treated with eptinezumab for migraine prevention: pooled data from four randomized, double-blind, placebo-controlled studies

Study Description Migraine Diagnosis Dosing Frequency Follow-up Visits
NCT01772524 [22] Phase 1b
DB/PC/PG/R
EM 1000 mg, placebo
Single dose (day 0)
Weeks 4, 8, 12, 24
NCT02275117 [23] Phase 2
DB/PC/PG/R
CM 10, 30, 100, 300 mg, placebo
Single dose (day 0)
Weeks 4, 8, 12, 24, 36, 49
PROMISE-1 (NCT02559895) [24] Phase 3
DB/PC/PG/R
EM 30, 100, 300 mg, placebo
Four doses (day 0, weeks 12, 24, 36)
Weeks 4, 8, 12, 16, 20, 24, 28, 36, 48, 56
PROMISE-2 (NCT02974153) [25] Phase 3
DB/PC/PG/R
CM 100, 300 mg, placebo
Two doses (day 0, week 12)
Weeks 2, 4, 8, 12, 16, 20, 24, 32
  1. DB Double-blind, PC Placebo-controlled, PG Parallel-group, R Randomized